News Today
Independent Medical Review Organization Determined: "Denial Should Be Overturned"
FAIRFIELD, CT / ACCESSWIRE / August 3, 2020 / Calmare Therapeutics Incorporated, (OTC PINK:CTTC), the pain mitigation company, announced today that the independent medical review organization ("IMRO"), in a rereview case filed with the California Department of Insurance, recommended overturning an insurance treatment coverage denial by the UnitedHealthcare Insurance Company for Calmare Pain Mitigation Therapy™ ("Calmare PMT") in the treatment of Complex Regional Pain Syndrome ("CRPS").
In the determination letter sent to a patient last month, the IMRO's final determination was as follows:
"FINAL DETERMINATION: OVERTURN. This means we disagree with UnitedHealthcare Insurance Company's decision to deny reimbursement for transcutaneous electrical modulation pain processing provided from 12/03/18 through 5/14/19. Two out of three medical experts decided that transcutaneous electrical modulation pain processing provided from 12/03/18 through 5/14/19 was likely to have been more beneficial for the enrollee than any available standard therapy."
Per CIC Section 10169.3(f), the California Department of Insurance adopts the decision of the IMRO. The IMRO decision is final and not subject to further appeals.
The patient was undergoing Calmare Pain Mitigation Therapy™ treatments for CRPS, under the supervision of Calmare Therapeutics Chief Medical Officer Dr. Stephen J. D'Amato, MD, FACEP.
"Calmare Pain Mitigation Therapy™ is the only effective, non-invasive and non-narcotic modality for CRPS today," said Calmare Therapeutics President & CEO Conrad Mir. "This overturning is monumental for the adoption of the Company's flagship, proprietary therapy within the medical community for CRPS. We look forward to having similar insurance coverage denials overturned."
